{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06044857",
            "orgStudyIdInfo": {
                "id": "STU-2023-0566"
            },
            "organization": {
                "fullName": "University of Texas Southwestern Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "PSMA PET Response Guided SabR in High Risk Pca",
            "officialTitle": "Phase IB Study of Personalized Ultrahypofractionated Stereotactic Ablative Radiotherapy of High Risk PROstate Cancer Guided by PET PSMA (68Ga PMSA-11; Ilucix) Response (PULSAR ProPhet)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "psma-pet-response-guided-sabr-in-high-risk-pca"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-27",
            "studyFirstSubmitQcDate": "2023-09-12",
            "studyFirstPostDateStruct": {
                "date": "2023-09-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Neil Desai",
                "investigatorTitle": "Associate Professor",
                "investigatorAffiliation": "University of Texas Southwestern Medical Center"
            },
            "leadSponsor": {
                "name": "University of Texas Southwestern Medical Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Once Upon a Time Foundation",
                    "class": "OTHER"
                },
                {
                    "name": "Telix Pharmaceuticals (Innovations) Pty Limited",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose"
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Adenocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "SAbR Every other day",
                    "type": "EXPERIMENTAL",
                    "description": "SAbR given 2-3/week, at least every other day in spacing with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.",
                    "interventionNames": [
                        "Drug: 68-Ga PSMA11"
                    ]
                },
                {
                    "label": "PULSAR every week",
                    "type": "EXPERIMENTAL",
                    "description": "SAbR given 1/week, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.",
                    "interventionNames": [
                        "Drug: 68-Ga PSMA11"
                    ]
                },
                {
                    "label": "PULSAR every 2 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "SAbR given every 2 weeks, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.",
                    "interventionNames": [
                        "Drug: 68-Ga PSMA11"
                    ]
                },
                {
                    "label": "PULSAR every 3 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "SAbR given every 3 weeks, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.",
                    "interventionNames": [
                        "Drug: 68-Ga PSMA11"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "68-Ga PSMA11",
                    "description": "Will be injected/assessed in line with its FDA label.",
                    "armGroupLabels": [
                        "PULSAR every 2 weeks",
                        "PULSAR every 3 weeks",
                        "PULSAR every week",
                        "SAbR Every other day"
                    ],
                    "otherNames": [
                        "Illucix, Telix"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Evaluation of Target Intra-Prostatic Lesion(s)",
                    "description": "This study primarily evaluates volume reduction of initial target PSMA-avid dominant intra-prostatic disease after neoadjuvant ADT and during SAbR in differing spacing regimens of SAbR.\n\nMetrics include percent reduction in volume at 3 months of therapy vs initial disease extent of intra-prostatic dominant lesion as identified by PSMA PET.",
                    "timeFrame": "Through end of neoadjuvant ADT at 3 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n-Pathologically confirmed adenocarcinoma of the prostate (within 180 days of registration) of high risk by national comprehensive cancer network (NCCN) criteria as determined by \\>=cT3a stage (AJCC 8th edition) OR PSA\\>20ng/mL OR ISUP Grade Group 4-5 (Gleason Grade 8-10).\n\nAge \u2265 18 years.\n\n* Planned for definitive intent stereotactic ablative radiotherapy (SabR) with integrated dose boost to intra-prostatic tumor and androgen deprivation therapy (ADT) with baseline AUA IPSS \\<=18 and prostate size \\<=100cc\n* Staging 68Ga PMSA-11 PET -CT or -MRI performed within 90 days of registration and before initiation of anti-androgen or androgen deprivation therapy and demonstrating no evidence of distant metastases by (PMSA avid or non-avid nodes \\<=1.5cm short axis allowed). Conventional imaging (CT, bone scan, MRI) may also be used in addition to PMSA-PET, and definitive findings of distant extra-pelvic metastases on these scans are not allowed for enrollment.\n* Staging 68Ga PSMA-11 PET -CT or -MRI demonstrating a PSMA-avid primary intra-prostatic target lesion amenable at investigator discretion to dose boost\n* All men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of standard of care SabR and for a period of time of 6 months thereafter as per standard guidelines. Should a man's partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Prior curative intent local therapy (e.g. prostatectomy, radiotherapy, focal ablative therapy) for prostate cancer is not allowed, with following exceptions regarding androgen deprivation therapy (ADT)/anti-androgen therapy (AAT):\n\nPrior androgen deprivation therapy (ADT) allowed if \\<3 month total duration and stopped \\>=3 months prior to registration with demonstration of non-castrate testosterone recovery (\\>50ng/dL) and meeting all other inclusion criteria.\n\nOngoing androgen deprivation therapy (ADT) is allowed if \\<=60 days total duration AND meeting following criteria:\n\nIf GnRH agonist used (e.g. leuprolide), bicalutamide must have been used for at least 30 days +/-14 days from start of GnRH agonist.\n\nAll other inclusion criteria.\n\n* Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.\n* History of allergic reactions to PMSA-11 68Ga imaging agent.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.\n* Prior pelvic radiotherapy other than cutaneous/superficial treatments.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sarah Neufeld",
                    "role": "CONTACT",
                    "phone": "214-645-8525",
                    "email": "Sarah.hardee@utsouthwestern.edu"
                },
                {
                    "name": "Liliana Robles",
                    "role": "CONTACT",
                    "phone": "214-645-8525",
                    "email": "liliana.robles@utsouthwestern.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Neil Desai, MD MHS",
                    "affiliation": "Study Principal Investigator",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Texas Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "UT Southwestern Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Neufeld",
                            "role": "CONTACT",
                            "phone": "214-648-1836",
                            "email": "Sarah.Neufeld@utsouthwestern.edu"
                        },
                        {
                            "name": "Liliana Robles",
                            "role": "CONTACT",
                            "phone": "214-648-1836",
                            "email": "Liliana.Robles@utsouthwestern.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000718244",
                    "term": "Gallium 68 PSMA-11"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019275",
                    "term": "Radiopharmaceuticals"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M352637",
                    "name": "Gallium 68 PSMA-11",
                    "asFound": "70%",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21258",
                    "name": "Radiopharmaceuticals",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}